Difficulty: Medium
Average Score: 92%
Practice
Which of the following drugs used in Parkinson's disease is a peripherally acting dopa decarboxylase inhibitor?
Correct answer
D
Rationale
The correct answer is D) Carbidopa. Carbidopa is a peripherally acting dopa decarboxylase inhibitor commonly used in combination with levodopa to treat Parkinson's disease. It works by preventing the conversion of levodopa into dopamine outside the brain, thus allowing more levodopa to reach the brain and be converted to dopamine centrally.
Option A) Levodopa is the precursor to dopamine and is converted to dopamine in the brain. It needs to be combined with carbidopa to enhance its effectiveness by preventing its breakdown in the periphery.
Option B) Bromocriptine is a dopamine agonist that directly stimulates dopamine receptors in the brain, but it is not a peripherally acting dopa decarboxylase inhibitor.
Option C) Amantadine is an antiviral agent with anti-Parkinsonian effects through its actions on dopamine release and reuptake, but it is not a peripherally acting dopa decarboxylase inhibitor.
Understanding the mechanism of action of drugs used in Parkinson's disease is crucial for healthcare providers to make informed decisions regarding treatment options for patients. Knowing the specific roles of medications like carbidopa in enhancing the efficacy of levodopa can lead to better management of symptoms and improved patient outcomes.
Option A) Levodopa is the precursor to dopamine and is converted to dopamine in the brain. It needs to be combined with carbidopa to enhance its effectiveness by preventing its breakdown in the periphery.
Option B) Bromocriptine is a dopamine agonist that directly stimulates dopamine receptors in the brain, but it is not a peripherally acting dopa decarboxylase inhibitor.
Option C) Amantadine is an antiviral agent with anti-Parkinsonian effects through its actions on dopamine release and reuptake, but it is not a peripherally acting dopa decarboxylase inhibitor.
Understanding the mechanism of action of drugs used in Parkinson's disease is crucial for healthcare providers to make informed decisions regarding treatment options for patients. Knowing the specific roles of medications like carbidopa in enhancing the efficacy of levodopa can lead to better management of symptoms and improved patient outcomes.